Diane Isabelle Magno Cavalcante

Dr. Diane Isabelle Magno Cavalcante

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
PGPaulo C. Giraldo
Paulo C. Giraldo
JJJOSE Eleutério Junior
JOSE Eleutério Junior
Diane Isabelle Magno CavalcanteDiane Isabelle Magno Cavalcante
Diane Isabelle Magno Cavalcante
AGAna Katherine Da Silveira Gonçalves
Ana Katherine Da Silveira Gonçalves
JRJuliana A.A. Romão
Juliana A.A. Romão
RERenata M.N. Eleutério
Renata M.N. Eleutério

28 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LPLuiza Darla Aguiar Silva Paiva
Luiza Darla Aguiar Silva Paiva
ATAna Carolina Filgueiras Teles
Ana Carolina Filgueiras Teles
JSJeferson dos Santos Souza
Jeferson dos Santos Souza
POPedro Ruan Amorim Oliveira
Pedro Ruan Amorim Oliveira
BSBIANCA ELEN SOUZA
BIANCA ELEN SOUZA
Deysi WongDeysi Wong
Deysi Wong
Background/Objectives: Inflammatory breast carcinoma (IBC) is an aggressive and rare neoplasm, accounting for 1–5% of all breast cancers. Toll-like receptor type 4 (TLR4) and Advanced Glycation End Products Receptor (AGER/RAGE) have been implicated in breast cancer, and have been shown to promote tumor growth, metastasis, and resistance to therapy by modulating the tumor microenvironment and inflammatory pathways. However, the role of TLR4 and AGER in IBC has not been elucidated. Methods: TLR4 and AGER immunofluorescence expression were evaluated in 27 IBC and 24 non-IBC samples. The expression data and clinicopathological parameters, including the prognostic values of these biomarkers, were compared. TLR4 and AGER gene expression were investigated using the microarray transcriptomic dataset of IBC and non-IBC samples (Gene Expression Omnibus repository—GEO). Results: IBC samples showed higher TLR4 and AGER immunoexpression than the non-IBC group and were associated with obesity and Ki-67 expression (p < 0.05). AGER expression in IBC versus non-IBC was also statistically associated with triple-negative molecular subtypes. Non-IBC subjects with AGER immunoexpression above the cutoff (106.1%, sensitivity of 92.3%, and specificity of 56.2%) showed reduced metastasis-free survival (p = 0.032). In the multivariate analysis, high TLR4 immunostaining increased the risk of metastasis-free survival by 1.029-fold. Analyzing three external GEO datasets confirmed that TLR4 and AGER expression increased in IBC compared to non-IBC samples. Conclusions: Overall, IBC samples showed higher TLR4 and AGER expressions than other breast cancer types, shedding light on the significance of these markers on IBC biology.

31 October 2025 in Revista de Medicina da UFC
Verified
Journal Article
Open access
PDF file
FRFernanda de Oliveira Rocha
Fernanda de Oliveira Rocha
Diane Isabelle Magno CavalcanteDiane Isabelle Magno Cavalcante
Diane Isabelle Magno Cavalcante
TNTeresa Neuma Albuquerque Gomes Nogueira
Teresa Neuma Albuquerque Gomes Nogueira
EGErika Ferreira Gomes
Erika Ferreira Gomes
Introdução: A zigomicose nasofacial é uma infecção fúngica rara do tecido subcutâneo que afeta os tecidos moles da face e os seios paranasais em áreas tropicais e subtropicais. Relato: O caso apresentado é de uma paciente do sexo feminino, 19 anos, residente no Nordeste do Brasil, com resposta plena ao tratamento clínico com monoterapia com Itraconazol. Discussão: O caso destaca uma apresentação atípica de zigomicose nasofacial, uma doença rara e pouco mencionada na literatura, mais comum em homens com ocupações agrícolas. Apesar da cultura negativa, o diagnóstico foi confirmado por achados clínicos e histopatológicos, além de uma resposta rápida ao Itraconazol. Conclusões: o diagnóstico precoce de zigomicose nasofacial em paciente imunocompetente pode evitar deformidades faciais permanentes e outras sequelas.

28 May 2026 in Human Genome Variation
Verified
Journal Article
Open access
APAbílio Alonso Colares Perez
Abílio Alonso Colares Perez
LCLaura Pinheiro Correia
Laura Pinheiro Correia
RCRégis Ponte Conrado
Régis Ponte Conrado
VMVinícius Nascimento Malheiro
Vinícius Nascimento Malheiro
CHCarlos Gustavo Hirth
Carlos Gustavo Hirth
DMDanielle Calheiros Campelo Maia
Danielle Calheiros Campelo Maia
Carney complex is a rare multiple neoplasia syndrome caused primarily by inactivating variants in the PRKAR1A gene, which encodes the regulatory subunit type I alpha of protein kinase A. Although classically associated with myxomas, lentigines, and endocrine tumors, the full tumor spectrum related to PRKAR1A loss of function is not completely defined. Here, we report a patient with a molecularly confirmed diagnosis of Carney complex carrying a de novo PRKAR1A (NM_002734.5):c.348+1G>A splice-site variant. In addition to typical manifestations, the patient developed two uncommon malignancies: invasive breast carcinoma (luminal B-like) at a young age and fibrolamellar hepatocellular carcinoma lacking the DNAJB1–PRKACA fusion typically found in sporadic cases. The coexistence of these two rare tumors in a single carrier of a pathogenic PRKAR1A variant expands the phenotypic variability associated with this condition and supports the possibility that PRKAR1A loss contributes to oncogenesis beyond the classical endocrine and mesenchymal tissues. This Data Report provides clinically relevant documentation of an unusual tumor presentation associated with a pathogenic PRKAR1A variant and underscores the importance of ongoing clinical surveillance in affected individuals.

7 April 2026 in Mastology
Verified
Journal Article
Open access
PDF file
ECEmmanuel Filizola Cavalcante
Emmanuel Filizola Cavalcante
JLJose Juvenal Linhares
Jose Juvenal Linhares
LRLuciana Gomes da Rocha
Luciana Gomes da Rocha
SOSilvando Carmo de Oliveira
Silvando Carmo de Oliveira
FMFernando Daniel de Oliveira Mayorga
Fernando Daniel de Oliveira Mayorga
Diane Isabelle Magno CavalcanteDiane Isabelle Magno Cavalcante
Diane Isabelle Magno Cavalcante
Introduction: Fine-needle aspiration or core needle biopsy guided by ultrasound of the axilla can provide crucial information for the treatment of breast cancer. Methods: This prospective phase 1 real-world study evaluated the effectiveness of the triple test, physical examination (PE), ultrasound (US), and ultrasound-guided fine-needle aspiration (USFNA) or ultrasound-guided core needle biopsy (USCNB) in predicting axillary metastases. It also explored the possibility of omitting axillary surgery based on negative results. The study included patients with high-penetrance mutations, ductal carcinoma in situ, or invasive breast cancer (cT1–4, axillary cN0–2), all of whom underwent aspiration or biopsy along with lymph node marking (using charcoal or clips), followed by sentinel lymph node biopsy and/or axillary dissection. Results: A total of 363 lymph nodes were dissected in 43 patients. The sensitivity of PE and US was 33.3% and 53.3%, respectively. When combining USFNA/USCNB with PE and US, sensitivity increased from 66.67% to 80%. Among patients with mutations or ductal carcinoma in situ or invasive cancer (cT1–4), when all three methods (PE, US, and USFNA/USCNB) were negative, the rate of positive lymph nodes was only 10%. Conclusions: Relying solely on PE, US, or USFNA/USCNB has limitations in detecting axillary metastases. Incorporating USFNA/USCNB significantly improved sensitivity and decreased false-negative rates. When all three methods were negative, the rate of axillary involvement was only 10%, indicating that axillary surgery could potentially be omitted. However, further studies are needed to validate these methods as reliable predictive tools for treatment decisions.

7 April 2026 in Mastology
Verified
Journal Article
Open access
ECEmmanuel Filizola Cavalcante
Emmanuel Filizola Cavalcante
JLJose Juvenal Linhares
Jose Juvenal Linhares
LRLuciana Gomes da Rocha
Luciana Gomes da Rocha
SOSilvando Carmo de Oliveira
Silvando Carmo de Oliveira
FMFernando Daniel de Oliveira Mayorga
Fernando Daniel de Oliveira Mayorga
Diane Isabelle Magno CavalcanteDiane Isabelle Magno Cavalcante
Diane Isabelle Magno Cavalcante
Introduction: Fine-needle aspiration or core needle biopsy guided by ultrasound of the axilla can provide crucial information for the treatment of breast cancer. Methods: This prospective phase 1 real-world study evaluated the effectiveness of the triple test, physical examination (PE), ultrasound (US), and ultrasound-guided fine-needle aspiration (USFNA) or ultrasound-guided core needle biopsy (USCNB) in predicting axillary metastases. It also explored the possibility of omitting axillary surgery based on negative results. The study included patients with high-penetrance mutations, ductal carcinoma in situ, or invasive breast cancer (cT1–4, axillary cN0–2), all of whom underwent aspiration or biopsy along with lymph node marking (using charcoal or clips), followed by sentinel lymph node biopsy and/or axillary dissection. Results: A total of 363 lymph nodes were dissected in 43 patients. The sensitivity of PE and US was 33.3% and 53.3%, respectively. When combining USFNA/USCNB with PE and US, sensitivity increased from 66.67% to 80%. Among patients with mutations or ductal carcinoma in situ or invasive cancer (cT1–4), when all three methods (PE, US, and USFNA/USCNB) were negative, the rate of positive lymph nodes was only 10%. Conclusions: Relying solely on PE, US, or USFNA/USCNB has limitations in detecting axillary metastases. Incorporating USFNA/USCNB significantly improved sensitivity and decreased false-negative rates. When all three methods were negative, the rate of axillary involvement was only 10%, indicating that axillary surgery could potentially be omitted. However, further studies are needed to validate these methods as reliable predictive tools for treatment decisions.